Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.55 |
| ▸ | BCR | P11274 | 4/20 | 0.55 |
| ▸ | JAK2 | O60674 | 4/20 | 0.51 |
| ▸ | JAK3 | P52333 | 4/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.51 |
| ▸ | GALR2 | O43603 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | RAF1 | P04049 | 4/20 | 0.46 |
| ▸ | BRAF | P15056 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996650 | 0.91 | ABL1 (0.56) | ABL1BCRJAK2JAK3PTK2 | |
| SCHEMBL3450413 | 0.86 | ABL1 (0.56) | ABL1BCRJAK2GALR2CTSS | |
| SCHEMBL3995077 | 0.85 | ABL1 (0.60) | ABL1BCRJAK2JAK3PTK2 | |
| SCHEMBL13621815 | 0.82 | ABL1 (0.58) | ABL1BCRJAK2JAK3PTK2 | |
| SCHEMBL3452936 | 0.81 | ABL1 (0.63) | ABL1BCRBRAF | |
| SCHEMBL3996127 | 0.79 | ABL1 (0.70) | ABL1BCRBRAF | |
| SCHEMBL4358479 | 0.76 | ABL1 (0.55) | ABL1BCRCTSSCTSKRAF1 | |
| SCHEMBL4119573 | 0.76 | ABL1 (0.61) | ABL1BCRJAK2JAK3PTK2 | |
| SCHEMBL13621927 | 0.75 | ABL1 (0.61) | ABL1BCRJAK2JAK3PTK2 | |
| SCHEMBL3450806 | 0.75 | JAK2 (0.61) | JAK2JAK3PTK2RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | claimed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-7820654-B2 | Pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-10-26 | — | — | US | disclosed |
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084645-A1 | Novel pyrimidine compounds, process for their preparation and compositions containing them | UMPS, DPYD, TYMS | ABL1 4436/4885BCR 1492/4885JAK2 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.